Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach - PubMed (original) (raw)
Comparative Study
doi: 10.1074/mcp.M500178-MCP200. Epub 2005 Oct 8.
Troels Zakarias Kristiansen, Akiko Iwahori, Rubens Chang, Raghunath Reddy, Norihiro Sato, Henrik Molina, Ole Nørregaard Jensen, Ralph H Hruban, Michael G Goggins, Anirban Maitra, Akhilesh Pandey
Affiliations
- PMID: 16215274
- DOI: 10.1074/mcp.M500178-MCP200
Free article
Comparative Study
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach
Mads Grønborg et al. Mol Cell Proteomics. 2006 Jan.
Free article
Abstract
Quantitative proteomics can be used as a screening tool for identification of differentially expressed proteins as potential biomarkers for cancers. Candidate biomarkers from such studies can subsequently be tested using other techniques for use in early detection of cancers. Here we demonstrate the use of stable isotope labeling with amino acids in cell culture (SILAC) method to compare the secreted proteins (secretome) from pancreatic cancer-derived cells with that from non-neoplastic pancreatic ductal cells. We identified 145 differentially secreted proteins (>1.5-fold change), several of which were previously reported as either up-regulated (e.g. cathepsin D, macrophage colony stimulation factor, and fibronectin receptor) or down-regulated (e.g. profilin 1 and IGFBP-7) proteins in pancreatic cancer, confirming the validity of our approach. In addition, we identified several proteins that have not been correlated previously with pancreatic cancer including perlecan (HSPG2), CD9 antigen, fibronectin receptor (integrin beta1), and a novel cytokine designated as predicted osteoblast protein (FAM3C). The differential expression of a subset of these novel proteins was validated by Western blot analysis. In addition, overexpression of several proteins not described previously to be elevated in human pancreatic cancer (CD9, perlecan, SDF4, apoE, and fibronectin receptor) was confirmed by immunohistochemical labeling using pancreatic cancer tissue microarrays suggesting that these could be further pursued as potential biomarkers. Lastly the protein expression data from SILAC were compared with mRNA expression data obtained using gene expression microarrays for the two cell lines (Panc1 and human pancreatic duct epithelial), and a correlation coefficient (r) of 0.28 was obtained, confirming previously reported poor associations between RNA and protein expression studies.
Similar articles
- SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.
Kashyap MK, Harsha HC, Renuse S, Pawar H, Sahasrabuddhe NA, Kim MS, Marimuthu A, Keerthikumar S, Muthusamy B, Kandasamy K, Subbannayya Y, Prasad TS, Mahmood R, Chaerkady R, Meltzer SJ, Kumar RV, Rustgi AK, Pandey A. Kashyap MK, et al. Cancer Biol Ther. 2010 Oct 15;10(8):796-810. doi: 10.4161/cbt.10.8.12914. Epub 2010 Oct 15. Cancer Biol Ther. 2010. PMID: 20686364 Free PMC article. - Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma.
Cui Y, Zhang D, Jia Q, Li T, Zhang W, Han J. Cui Y, et al. Cancer Invest. 2009 Aug;27(7):747-55. doi: 10.1080/07357900802672746. Cancer Invest. 2009. PMID: 19488907 - Secretome Proteomic Approaches for Biomarker Discovery: An Update on Colorectal Cancer.
Cevenini A, Orrù S, Imperlini E. Cevenini A, et al. Medicina (Kaunas). 2020 Aug 31;56(9):443. doi: 10.3390/medicina56090443. Medicina (Kaunas). 2020. PMID: 32878319 Free PMC article. Review. - Proteome-based biomarkers in pancreatic cancer.
Sun C, Rosendahl AH, Ansari D, Andersson R. Sun C, et al. World J Gastroenterol. 2011 Nov 28;17(44):4845-52. doi: 10.3748/wjg.v17.i44.4845. World J Gastroenterol. 2011. PMID: 22171124 Free PMC article. Review.
Cited by
- Predegenerated Schwann cells--a novel prospect for cell therapy for glaucoma: neuroprotection, neuroregeneration and neuroplasticity.
Smedowski A, Liu X, Pietrucha-Dutczak M, Matuszek I, Varjosalo M, Lewin-Kowalik J. Smedowski A, et al. Sci Rep. 2016 Apr 1;6:23187. doi: 10.1038/srep23187. Sci Rep. 2016. PMID: 27034151 Free PMC article. - Analysis of endoscopic pancreatic function test (ePFT)-collected pancreatic fluid proteins precipitated via ultracentrifugation.
Paulo JA, Kadiyala V, Gaun A, Sauld JF, Ghoulidi A, Banks PA, Steen H, Conwell DL. Paulo JA, et al. JOP. 2013 Mar 10;14(2):176-86. doi: 10.6092/1590-8577/1272. JOP. 2013. PMID: 23474565 Free PMC article. - Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.
Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, Milless BP, Goodlett DR, Rush J, Brentnall TA. Pan S, et al. J Proteome Res. 2012 Mar 2;11(3):1937-48. doi: 10.1021/pr201117w. Epub 2012 Feb 8. J Proteome Res. 2012. PMID: 22316387 Free PMC article. - Immunoscreening of the extracellular proteome of colorectal cancer cells.
Klein-Scory S, Kübler S, Diehl H, Eilert-Micus C, Reinacher-Schick A, Stühler K, Warscheid B, Meyer HE, Schmiegel W, Schwarte-Waldhoff I. Klein-Scory S, et al. BMC Cancer. 2010 Feb 25;10:70. doi: 10.1186/1471-2407-10-70. BMC Cancer. 2010. PMID: 20184735 Free PMC article. - A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts.
Coleman O, Henry M, O'Neill F, Roche S, Swan N, Boyle L, Murphy J, Meiller J, Conlon NT, Geoghegan J, Conlon KC, Lynch V, Straubinger NL, Straubinger RM, McVey G, Moriarty M, Meleady P, Clynes M. Coleman O, et al. Proteomes. 2018 Nov 6;6(4):45. doi: 10.3390/proteomes6040045. Proteomes. 2018. PMID: 30404163 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous